"Duloxetine Hydrochloride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A thiophene derivative and selective NEUROTRANSMITTER UPTAKE INHIBITOR for SEROTONIN and NORADRENALINE (SNRI). It is an ANTIDEPRESSIVE AGENT and ANXIOLYTIC, and is also used for the treatment of pain in patients with DIABETES MELLITUS and FIBROMYALGIA.
Descriptor ID |
D000068736
|
MeSH Number(s) |
D02.886.778.260 D03.383.903.260
|
Concept/Terms |
Duloxetine- Duloxetine
- N-methyl-3-(1-naphthalenyloxy)-3-(2-thiophene)propanamide
- N-methyl-3-(1-naphthalenyloxy)-2-thiophenepropanamine
|
Below are MeSH descriptors whose meaning is more general than "Duloxetine Hydrochloride".
Below are MeSH descriptors whose meaning is more specific than "Duloxetine Hydrochloride".
This graph shows the total number of publications written about "Duloxetine Hydrochloride" by people in this website by year, and whether "Duloxetine Hydrochloride" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2005 | 0 | 1 | 1 |
2006 | 0 | 1 | 1 |
2008 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Duloxetine Hydrochloride" by people in Profiles.
-
Kaszuba BC, Walling I, Gee LE, Shin DS, Pilitsis JG. Effects of subthalamic deep brain stimulation with duloxetine on mechanical and thermal thresholds in 6OHDA lesioned rats. Brain Res. 2017 01 15; 1655:233-241.
-
Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014 Jun 20; 32(18):1941-67.
-
Ji D, Gilpin NW, Richardson HN, Rivier CL, Koob GF. Effects of naltrexone, duloxetine, and a corticotropin-releasing factor type 1 receptor antagonist on binge-like alcohol drinking in rats. Behav Pharmacol. 2008 Feb; 19(1):1-12.
-
Wu EQ, Birnbaum HG, Mareva MN, Le TK, Robinson RL, Rosen A, Gelwicks S. Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain. J Pain. 2006 Jun; 7(6):399-407.
-
Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, Wernicke JF. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005 Dec 15; 119(1-3):5-15.